Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Rodríguez-Pallares, Salud
Outeda-García, Michelle
Lence, Emilio
Rodríguez-Coello, Arianna
González-Pinto, Lucía
Guijarro-Sánchez, Paula
Báez-Barroso, Gabriela Alejandra
Blanco Martín, Tania
Vázquez-Ucha, Juan Carlos
Llanos, Agustina

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, Báez-Barroso GA, Blanco-Martín T, Vázquez-Ucha JC, Llanos A, Sannio F, Docquier J-D, Morrisey I, Hawser S, Zalacain M, Lemonnier M, González-Bello C, Bou G, Beceiro A, Arca-Suárez J. Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). Antimicrob Agents Chemother. 2026 Apr;70(4):e0169125

Type of academic work

Academic degree

Abstract

[Abstract] Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant (Kd ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH-F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections.

Description

Rights

Attribution 4.0 International
Attribution 4.0 International

Except where otherwise noted, this item's license is described as Attribution 4.0 International